Abstract
Nephrotoxicity is the most common side effect that severely limits the clinical application of tacrolimus (TAC), an immunosuppressive agent used in kidney transplant patients. This study aimed to explore the tolerated dose of nephrotoxicity of TAC in individuals with different CYP3A5 genotypes and liver conditions. We established a human whole-body physiological pharmacokinetic (WB-PBPK) model and validated it using data from previous clinical studies. Following the injection of 1 mg/kg TAC into the tail veins of male rats, we developed a rat PBPK model utilizing the drug concentration–time curve obtained by LC–MS/MS. Next, we converted the established rat PBPK model into the human kidney PBPK model. To establish renal concentrations, the BMCL5 of the in vitro CCK-8 toxicity response curve (drug concentration range: 2–80 mol/L) was extrapolated. To further investigate the acceptable levels of nephrotoxicity for several distinct CYP3A5 genotypes and varied hepatic function populations, oral dosing regimens were extrapolated utilizing in vitro-in vivo extrapolation (IVIVE). The PBPK model indicated the tolerated doses of nephrotoxicity were 0.14–0.185 mg/kg (CYP3A5 expressors) and 0.13–0.155 mg/kg (CYP3A5 non-expressors) in normal healthy subjects and 0.07–0.09 mg/kg (CYP3A5 expressors) and 0.06–0.08 mg/kg (CYP3A5 non-expressors) in patients with mild hepatic insufficiency. Further, patients with moderate hepatic insufficiency tolerated doses of 0.045–0.06 mg/kg (CYP3A5 expressors) and 0.04–0.05 mg/kg (CYP3A5 non-expressors), while in patients with moderate hepatic insufficiency, doses of 0.028–0.04 mg/kg (CYP3A5 expressors) and 0.022–0.03 mg/kg (CYP3A5 non-expressors) were tolerated. Overall, our study highlights the combined usage of the PBPK model and the IVIVE approach as a valuable tool for predicting toxicity tolerated doses of a drug in a specific group.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All the data in this article will be made available on request to the corresponding author (lincuihong1974@sina.com).
References
Abdullah R, Alhusainy W, Woutersen J, Rietjens IMCM, Punt A (2016) Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: the case of kidney toxicity induced by aristolochic acid I. Food Chem Toxicol 92:104–116. https://doi.org/10.1016/j.fct.2016.03.017
Algharably EAE-H, Di Consiglio E, Testai E, Kreutz R, Gundert-Remy U (2021) Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. Arch Toxicol 95:1433–1442. https://doi.org/10.1007/s00204-021-02989-2
Balazki P, Schaller S, Eissing T, Lehr T (2018) A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors. CPT Pharmacometrics Syst Pharmacol 7:788–797. https://doi.org/10.1002/psp4.12359
Balhara A, Ladumor MK, Nankar RP, Syed SD, Giri S, Prasad B, Singh S (2022) Exploration of the plausible mechanism of ethambutol induced ocular toxicity by using proteomics informed physiologically based pharmacokinetic (PBPK) modeling. Pharm Res 39:677–689. https://doi.org/10.1007/s11095-022-03227-9
Barter ZE, Tucker GT, Rowland-Yeo K (2013) Differences in cytochrome P450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet 52:1085–1100. https://doi.org/10.1007/s40262-013-0089-y
Bekersky I, Dressler D, Alak A, Boswell GW, Mekki QA (2001) Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. J Clin Pharmacol 41:628–635. https://doi.org/10.1177/00912700122010519
Bentata Y (2020) Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs 44:140–152. https://doi.org/10.1111/aor.13551
Braithwaite HE, Darley DR, Brett J, Day RO, Carland JE (2021) Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: a systematic review. Transplant Rev (Orlando) 35:100610. https://doi.org/10.1016/j.trre.2021.100610
Buur JL, Baynes RE, Riviere JE (2008) Estimating meat withdrawal times in pigs exposed to melamine contaminated feed using a physiologically based pharmacokinetic model. Regul Toxicol Pharmacol 51:324–331. https://doi.org/10.1016/j.yrtph.2008.05.003
Chang X, Tan Y-M, Allen DG, Bell S, Brown PC, Browning L, Ceger P, Gearhart J, Hakkinen PJ, Kabadi SV, Kleinstreuer NC, Lumen A, Matheson J, Paini A, Pangburn HA, Petersen EJ, Reinke EN, Ribeiro AJS, Sipes N, Sweeney LM, Wambaugh JF, Wange R, Wetmore BA, Mumtaz M (2022) IVIVE: facilitating the use of in vitro toxicity data in risk assessment and decision making. Toxics 10:232. https://doi.org/10.3390/toxics10050232
Chen Y, Ke M, Xu J, Lin C (2020) Simulation of the pharmacokinetics of oseltamivir and its active metabolite in normal populations and patients with hepatic cirrhosis using physiologically based pharmacokinetic modeling. AAPS Pharm Sci Tech 21:98. https://doi.org/10.1208/s12249-020-1638-y
Chen W-Y, Evangelista EA, Yang J, Kelly EJ, Yeung CK (2021) Kidney organoid and microphysiological kidney chip models to accelerate drug development and reduce animal testing. Front Pharmacol 12:695920. https://doi.org/10.3389/fphar.2021.695920
Choi Y, Jiang F, An H, Park HJ, Choi JH, Lee H (2017) A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform. Pharmacogenomics J 17:105–106. https://doi.org/10.1038/tpj.2016.85
de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR (2012) In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 92:366–375. https://doi.org/10.1038/clpt.2012.109
de Loor H, Vanhove T, Annaert P, Lescrinier E, Kuypers D (2021) Determination of tacrolimus, three mono-demethylated metabolites and a M1 tautomer in human whole blood by liquid chromatography—tandem mass spectrometry. J Pharm Biomed Anal 205:114296. https://doi.org/10.1016/j.jpba.2021.114296
Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu C-P, Stouch BJ, Hurh E, Gibbs MA (2011) Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50:131–142. https://doi.org/10.2165/11537430-000000000-00000
Edginton AN, Ahr G, Willmann S, Stass H (2009) Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Clin Pharmacokinet 48:181–187. https://doi.org/10.2165/00003088-200948030-00004
El-Khateeb E, Achour B, Al-Majdoub ZM, Barber J, Rostami-Hodjegan A (2021a) Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment. Mol Pharm 18:3563–3577. https://doi.org/10.1021/acs.molpharmaceut.1c00462
El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami-Hodjegan A (2021b) Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Aliment Pharmacol Ther 54:388–401. https://doi.org/10.1111/apt.16489
Emulate (2022) Proximal tubule kidney-chip for modeling human physiology [WWW Document]. URL https://emulatebio.com/kidney-chip/
Faria J, Ahmed S, Gerritsen KGF, Mihaila SM, Masereeuw R (2019) Kidney-based in vitro models for drug-induced toxicity testing. Arch Toxicol 93:3397–3418. https://doi.org/10.1007/s00204-019-02598-0
Gertz M, Houston JB, Galetin A (2011) Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39:1633–1642. https://doi.org/10.1124/dmd.111.039248
Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, Mantan M, Agarwal I, Dinda AK, Hari P, Bagga A (2012) Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 82:1130–1135. https://doi.org/10.1038/ki.2012.238
Imamura CK, Furihata K, Okamoto S, Tanigawara Y (2016) Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J Clin Pharmacol 56:408–413. https://doi.org/10.1002/jcph.605
Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A (2010) A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 49:189–206. https://doi.org/10.2165/11318160-000000000-00000
Kamdem LK, Streit F, Zanger UM, Brockmöller J, Oellerich M, Armstrong VW, Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374–1381. https://doi.org/10.1373/clinchem.2005.050047
Kapturczak MH, Meier-Kriesche HU, Kaplan B (2004) Pharmacology of calcineurin antagonists. Transplant Proc 36:25S-32S. https://doi.org/10.1016/j.transproceed.2004.01.018
Kim YK, Kim A, Park SJ, Lee H (2017) New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients. Drug Des Devel Ther 11:2861–2869. https://doi.org/10.2147/DDDT.S142201
Knops N, Ramazani Y, Loor H, Goldschmeding R, Nguyen TQ, van den Heuvel LP, Levtchenko E, Kuypers DJ (2022) Tacrolimus induces a pro-fibrotic response in donor-derived human proximal tubule cells dependent on common variants of CYP3A5 and ABCB1 genes. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfac237
Kuypers DRJ, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y (2010) Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 32:394–404. https://doi.org/10.1097/FTD.0b013e3181e06818
Kwon M, Yeom D, Kim NA, Choi DH, Park J, Wang H, Yoo SD, Jeong SH (2015) Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. Arch Pharm Res 38:73–80. https://doi.org/10.1007/s12272-014-0343-3
Lin NYC, Homan KA, Robinson SS, Kolesky DB, Duarte N, Moisan A, Lewis JA (2019) Renal reabsorption in 3D vascularized proximal tubule models. Proc Natl Acad Sci USA 116:5399–5404. https://doi.org/10.1073/pnas.1815208116
Lu XF (2016) Evaluation of the influence of itraconazole on tacrolimus absorption and distribution using physiologically based pharmacokinetic model. Dissertation, Shenyang Pharmaceutical University.
Lu Y, Su Q, Wu K, Ren Y, Li L, Zhou T, Lu W (2015) A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin 36:281–288. https://doi.org/10.1038/aps.2014.110
Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, Christians U (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69:24–31. https://doi.org/10.1067/mcp.2001.113183
Matas AJ (2011) Calcineurin inhibitors: short-term friend, long-term foe? Clin Pharmacol Ther 90:209–211. https://doi.org/10.1038/clpt.2011.77
Mo X, Chen X, Ieong C, Gao X, Li Y, Liao X, Yang H, Li H, He F, He Y, Chen Y, Liang H, Huang M, Li J (2021) Early prediction of tacrolimus-induced tubular toxicity in pediatric refractory nephrotic syndrome using machine learning. Front Pharmacol 12:638724. https://doi.org/10.3389/fphar.2021.638724
Möller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T, Schäfer A, Undre NA (1999) The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 27:633–636
Nair A, Morsy MA, Jacob S (2018) Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. Drug Dev Res 79:373–382. https://doi.org/10.1002/ddr.21461
Nankivell BJ, P’Ng CH, O’Connell PJ, Chapman JR (2016) Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation 100:1723–1731. https://doi.org/10.1097/TP.0000000000001243
Niioka T, Kagaya H, Miura M, Numakura K, Saito M, Inoue T, Habuchi T, Satoh S (2013) Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol 69:1659–1665. https://doi.org/10.1007/s00228-013-1514-8
Ning J, Chen L, Strikwold M, Louisse J, Wesseling S, Rietjens IMCM (2019) Use of an in vitro-in silico testing strategy to predict inter-species and inter-ethnic human differences in liver toxicity of the pyrrolizidine alkaloids lasiocarpine and riddelliine. Arch Toxicol 93:801–818. https://doi.org/10.1007/s00204-019-02397-7
Noll BD, Coller JK, Somogyi AA, Morris RG, Russ GR, Hesselink DA, Van Gelder T, Sallustio BC (2013) Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Ther Drug Monit 35:617–623. https://doi.org/10.1097/FTD.0b013e31828e8162
Purohit HS, Trasi NS, Sun DD, Chow ECY, Wen H, Zhang X, Gao Y, Taylor LS (2018) Investigating the impact of drug crystallinity in amorphous tacrolimus capsules on pharmacokinetics and bioequivalence using discriminatory in vitro dissolution testing and physiologically based pharmacokinetic modeling and simulation. J Pharm Sci 107:1330–1341. https://doi.org/10.1016/j.xphs.2017.12.024
Qin XL, Chen X, Wang Y, Xue XP, Wang Y, Li JL, Wang XD, Zhong GP, Wang CX, Yang H, Huang M, Bi HC (2014) In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) on the CYP3A/P-glycoprotein-mediated absorption and metabolism of tacrolimus. Drug Metab Dispos 42:193–199. https://doi.org/10.1124/dmd.113.053892
Romano P, da Luz Fernandes M, De Almeida Rezende Ebner P, Duarte de Oliveira N, Mitsue Okuda L, Agena F, Mendes ME, Massakazu Sumita N, Coelho V, David-Neto E, Zocoler Galante N (2018) UPLC-MS/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+ and B CD19+ lymphocytes. J Pharm Biomed Anal 152:306–314. https://doi.org/10.1016/j.jpba.2018.01.002
Sallustio BC, Noll BD, Hu R, Barratt DT, Tuke J, Coller JK, Russ GR, Somogyi AA (2021) Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. Br J Clin Pharmacol 87:3901–3909. https://doi.org/10.1111/bcp.14806
Sawamoto K, Huong TT, Sugimoto N, Mizutani Y, Sai Y, Miyamoto K (2014) Mechanisms of lower maintenance dose of tacrolimus in obese patients. Drug Metab Pharmacokinet 29:341–347. https://doi.org/10.2133/dmpk.dmpk-13-rg-110
Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S (2018) Tacrolimus—pharmacokinetic considerations for clinicians. Curr Drug Metab 19:342–350. https://doi.org/10.2174/1389200219666180101104159
Scotcher D, Arya V, Yang X, Zhao P, Zhang L, Huang S-M, Rostami-Hodjegan A, Galetin A (2020) A novel physiologically based model of creatinine renal disposition to integrate current knowledge of systems parameters and clinical observations. CPT Pharmacometrics Syst Pharmacol 9:310–321. https://doi.org/10.1002/psp4.12509
Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623–653. https://doi.org/10.2165/00003088-200443100-00001
Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 49:207–221. https://doi.org/10.2165/11317550-000000000-00000
Tada H, Satoh S, Iinuma M, Shimoda N, Murakami M, Hayase Y, Kato T, Suzuki T (2003) Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 43:859–865. https://doi.org/10.1177/0091270003254797
Thölking G, Schütte-Nütgen K, Schmitz J, Rovas A, Dahmen M, Bautz J, Jehn U, Pavenstädt H, Heitplatz B, Van Marck V, Suwelack B, Reuter S (2019) A low tacrolimus concentration/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity. J Clin Med 8:1586. https://doi.org/10.3390/jcm8101586
Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Lipscomb JC, Schlosser P, Chiu WA, Krishnan K (2008) Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B Crit Rev 11:519–547. https://doi.org/10.1080/10937400701724337
Tian H, Ou J, Strom SC, Venkataramanan R (2005) Pharmacokinetics of tacrolimus and mycophenolic acid are altered, but recover at different times during hepatic regeneration in rats. Drug Metab Dispos 33:329–335. https://doi.org/10.1124/dmd.104.002287
Tsuchiya T, Ishida H, Tanabe T, Shimizu T, Honda K, Omoto K, Tanabe K (2013) Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective tri l in once-daily versus twice-daily tacrolimus. Transplantation 96:198–204. https://doi.org/10.1097/TP.0b013e318296c9d5
Vanhove T, Annaert P, Kuypers DRJ (2016) Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 48:88–112. https://doi.org/10.3109/03602532.2016.1151037
Wang D, Chen X, Fu M, Xu H, Li Z (2019) Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. Int J Mol Med 44:2181–2188. https://doi.org/10.3892/ijmm.2019.4368
Wang Q, Li M, Cheng X, Xu G (2021) Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy. Sci Rep 11:13274. https://doi.org/10.1038/s41598-021-92678-y
Yu L, Li H, Zhang C, Zhang Q, Guo J, Li J, Yuan H, Li L, Carmichael P, Peng S (2020) Integrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment-a case study of troglitazone. Environ Toxicol Pharmacol 74:103296. https://doi.org/10.1016/j.etap.2019.103296
Zhang Q, Li J, Middleton A, Bhattacharya S, Conolly RB (2018) Bridging the data gap from in vitro toxicity testing to chemical safety assessment through computational modeling. Front Public Health 6:261. https://doi.org/10.3389/fpubh.2018.00261
Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE (2012) Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther 92:737–745. https://doi.org/10.1038/clpt.2012.175
Acknowledgements
The research was supported by Joint Funds for the Innovation of Science and Technology, Fujian Province (No. 2020Y9009); Natural Science Foundation of Fujian Province (No. 2023J01600).
Author information
Authors and Affiliations
Contributions
LC, MK, HW and WW conducted the experiment and developed the PBPK model. MK, RL, and PH provided the discussion of the model and LC, MK and CL wrote the manuscript and CL designed the research.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interests in their authorship or publication of this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cai, L., Ke, M., Wang, H. et al. Physiologically based pharmacokinetic model combined with reverse dose method to study the nephrotoxic tolerance dose of tacrolimus. Arch Toxicol 97, 2659–2673 (2023). https://doi.org/10.1007/s00204-023-03576-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-023-03576-3